Clinical Trial Update: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing ibandronate with zoledronic acid for nephrotoxicity in multiple myeloma was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Ibandronate (ibandronate)
• Zoledronic acid (Zoledronic acid)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Myeloma | Phase 3 | Status: TERMINATED | Results posted: 2016-07-22